Many governments, including the U.S. and Japan, are well aware of the dangers to their populations of exposure to high levels of radiation from nuclear accidents or dirty bomb attacks. Whereas Japan’s population was recently exposed at Fukushima following the tsunami of 2011, the U.S. Department of Defense has been stockpiling acute radiation syndrome (ARS) countermeasures as a precaution for many years. [Read more…]
RoosterBio Commercializes Industry’s First cGMP Human MSC Banks For Widespread Manufacturing
RoosterBio Launches Only Commercially-Available Working Cell Banks (WCBs) for Large-Scale hMSC Production
Frederick, MD, USA. January 24, 2018 – RoosterBio Inc., a leading manufacturer of adult, allogeneic human mesenchymal stem/stromal cells (hMSCs) and paired bioprocess media systems, continues to deliver on its mission to de-bottleneck and accelerate the Regenerative Medicine Industry by launching the only commercially-available working cell banks (WCBs) for large scale hMSC production. [Read more…]
Exciting Early Results in Cynata’s UK Trial of iPSC-Derived MSC Therapeutic Product
Patients in Cohort A Respond Well, 1st Patient in Cohort B Dosed in Cynata’s CYP-001 Trial
Australian stem cell company, Cynata Therapeutics has released exciting early results from its ongoing clinical trial in the UK utilizing an iPS cell-derived mesenchymal stem cell (MSC) therapeutic product. [Read more…]
PolarityTE, Interview with Dr. Denver Lough, President and CEO
PolarityTE is an innovative company that has developed a platform to regenerate a variety of functionally polarized tissue substrates, such as skin, bone, muscle, cartilage, blood vessels, peripheral nerves, and more. I had the honor of interviewing Dr. Denver Lough, Chairman, President, CEO, and CSO of PolarityTE. In this interview, we explore the origins of PolarityTE as a company. We also explore the company’s novel technology, 5-year vision, and future directions. Enjoy. [Read more…]
Cytori Completes Enrollment for Habeo™ Cell Therapy for Scleroderma and Impaired Hand Function
-
Cytori developing cell therapies that harness the unique attributes of adipose-derived regenerative cells (ADRCs)
-
40 patients enrolled among 5 French centers: Marseille, Montpelier, Rouen, Lyon, and Paris
SAN DIEGO, Jan. 22, 2018 — Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces completion of patient enrollment in SCLERADEC II (NCT02558543), a randomized, double-blind, placebo-controlled, parallel group, multi-center clinical trial intended to study the safety and efficacy of Habeo™ Cell Therapy in up to 40 subjects with impaired hand function due to scleroderma (systemic sclerosis). [Read more…]
- « Previous Page
- 1
- …
- 244
- 245
- 246
- 247
- 248
- …
- 338
- Next Page »